Uluru said that the first shipment of Altrazeal has been received by its marketing partner in Australia.
Altrazeal, a wound treatment technology, has shown clinical and economic advantages in a number of chronic and acute wounds, which include diabetic foot ulcers, venous leg ulcers and geriatric wounds.
Uluru's Australian partner has been awarded the first state government contract inspite of Altrazeal's commercial unavailability in Australia.
Uluru president and CEO Kerry Gray said Uluru is excited with the advances that have been made in the Australian market.
''The clinical support that has been developed is impressive and further expands and validates the data that has been developed in both Europe and the United States," Gray added.
"The achievement of these significant milestones by our Australian partner are clear indications of the commercial potential for Altrazeal in government sponsored health care systems where products demonstrating cost effective patient outcomes are a high priority.''
Altrazeal initially will be available in a 2 gram pouch in the private market segment of Australia and it will be followed by 0.75 gram blister pack.
